Companies in #Pain (non-opioid)
Found 1 company operating in this sector.
Adial Pharmaceuticals (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, focused on therapeutics for addiction and related disorders. Its lead program, AD04, is a genetically targeted serotonin-3 receptor antagonist being advanced through a new Phase 3 clinical trial program for alcohol use disorder in patients with certain target genotypes. Following the June 2026 acquisition of Azora Therapeutics, the pipeline also includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist in development for ulcerative colitis, plus earlier-stage candidates for non-opioid pain reduction. On August 17, 2026, shares rose 25.38% after the company reported Q2 2026 results and a business update highlighting the Azora acquisition and the AD04 Phase 3 path.